The role of protamine amount in the transfection performance of cationic SLN designed as a gene nanocarrier by Vighi, Eleonora et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=idrd20
Download by: [Univ Modena e Reggio Emilia BU], [Eliana Leo] Date: 09 September 2015, At: 08:10
Drug Delivery
ISSN: 1071-7544 (Print) 1521-0464 (Online) Journal homepage: http://www.tandfonline.com/loi/idrd20
The role of protamine amount in the transfection
performance of cationic SLN designed as a gene
nanocarrier
Eleonora Vighi, Monica Montanari, Barbara Ruozi, Valentina Iannuccelli &
Eliana Leo
To cite this article: Eleonora Vighi, Monica Montanari, Barbara Ruozi, Valentina
Iannuccelli & Eliana Leo (2012) The role of protamine amount in the transfection
performance of cationic SLN designed as a gene nanocarrier, Drug Delivery, 19:1, 1-10, DOI:
10.3109/10717544.2011.621989
To link to this article:  http://dx.doi.org/10.3109/10717544.2011.621989
Published online: 09 Nov 2011.
Submit your article to this journal 
Article views: 117
View related articles 
Citing articles: 1 View citing articles 
1Introduction
Gene therapy requires the introduction of foreign DNA 
encoding a therapeutic gene into the target cells, using 
viral or non-viral delivery systems. Non-viral vectors, 
even if not so efficacious as viral ones, are safer and 
may be used in the in vivo approach, allowing the DNA 
administration by a systemic route such as intravenous 
infusion (Huang & Viroonchatapan, 1999; Morille et al., 
2008). Solid Lipid Nanoparticles (SLN) represent one 
of the most studied non-viral lipid vectors (Olbrich 
et al., 2001; Rudolph et al., 2004; Tabatt et al., 2004a, 
b; Pedersen et al., 2006; del Pozo-Rodriguez et al., 
2009). However, it is known that the transfection effi-
ciency of non-viral vectors, including SLN, is limited 
by several steps, such as cell internalization, disrup-
tion of the endosome membrane, and translocation of 
the genetic material towards the cell nucleus (Canine 
et al., 2008). In order to promote the transfection, 
cationic  non-viral vectors are described to facilitate an 
electrostatic interaction of the nanocarrier with both 
the negative backbone of DNA and the negative cell 
surface inducing unspecific endocythosis. For this rea-
son, cationic lipids such as Esterquat 1 (EQ1) (N,N-di-
(β-stearoylethyl)-N,N-dimethylammonium chloride) 
or DOTAP (N-(1-(2,3-dioleoyloxy) propyl)-N,N,N-
trimethylammoniumchloride) have been used in the 
development of cationic gene delivery devices (Olbrich 
et al., 2001; del Pozo-Rodriguez et al., 2007). Moreover, 
the addition of cationic protein/peptide transfection 
promoters, such as protamine, has been shown to 
enhance lipid-mediated gene transfection (Vangasseri 
et al., 2005). Protamine is a cationic nuclear protein 
enriched in arginine, FDA approved for the parenteral 
administration, and widely studied in the gene delivery 
(Tsuchiya et al., 2006) owing to its ability to improve 
DNA packaging in sperm cells (Braun, 2001), to protect 
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DNA from degradation and to promote DNA delivery 
into the nucleus by means of Nuclear Localization 
Signal sequence (Tsuchiya et al., 2006).
In previous studies, we referred that the transfection by 
SLN-Protamine:pDNA was more effective compared with 
the Protamine:pDNA polyplexes while no transfection 
capacity was observed for SLN-EQ1:pDNA complexes due 
to their inability to be internalized caused by their larger 
dimension (Vighi et al., 2010a). Red Nile-SLN-Protamine 
were localized in endocytic-like vesicles inside the nuclear 
membrane, suggesting that the inclusion of protamine in 
nano-lipophilic systems may reduce the complex size and 
enhance the nuclear pDNA translocation as well as the 
pDNA release into the cells (Vighi et al., 2010a, b).
Since the protamine concentration added to the 
SLN composition could represent a crucial param-
eter affecting the transfection efficiency, the present 
work aims to investigate the effect of the amount of 
protamine employed in the vector preparation on the in 
vitro performance of cationic SLN. These vectors were 
formulated using stearic acid as the solid lipid matrix, 
Pluronic F68 as the surfactant, and stearylamine as the 
cationic component. Protamine was included in three 
different percentages, i.e., 0.25, 1, and 2% w/v, obtain-
ing three different SLN samples. SLN physical prop-
erties (morphology, size, and zeta potential), pDNA 
complexation, as well as in vitro cytotoxicity and gene 
transfection ability were examined in order to establish 
the optimum protamine amount useful to enhance 
SLN transfection efficiency and expression level in a 
perspective of a gene therapy.
Materials and methods
Materials
Stearic acid was purchased from Carlo Erba Reagenti 
(Milan, Italy). Stearylamine was provided from Fluka 
(Deisenhofen, Germany). Protamine sulfate and poly-
ethilenimmine (PEI, Mw 25,000) were provided from 
Sigma-Aldrich (St. Louis, MO). Agarose GellyPhor, 
Dulbecco’s modified eagle medium (DMEM), Dulbecco’s 
Phosphate Buffer (PBS), and other culture reagents were 
purchased from Euroclone Celbio (Milan, Italy). All 
other chemical reagents were obtained commercially 
as reagent-grade products. The cell lines COS-I, HepG2, 
and Na1300 were provided from Zoo-prophylactic 
Institute of Emilia Romagna (Bologna, Italy).
SLN preparation
Cationic SLN were produced by a modification of the 
oil-in-water microemulsion method (Heydenrich 
et al., 2003). In practice, the solid lipid component 
(250 mg stearic acid) was melted at ~68°C, and an 
aqueous phase (10 mL) containing Pluronic F68 (2% 
w/v), stearylamine (3% w/v), and protamine (0.25, 1, or 
2% w/v) was heated at the same temperature. Then, the 
melted lipid phase was dispersed in the aqueous phase 
using a high-speed stirrer (Ultra-Turrax T25, IkaWerk, 
Staufen, Germany) at 20,500 rpm for 5 min to obtain a 
hot O/W emulsion. The emulsion was then cooled at 4°C 
by an ice bath under mechanical stirring at 20,500 rpm 
for 10 min, i.e., until the formation of solid lipid nano-
particles (SLN) suspension. This suspension was puri-
fied and concentrated until 10 mL volume by vacuum 
ultra-filtration using a polycarbonate holder (Sartorius, 
Goettingen, Germany) equipped with a polyether-
sulfone (PESU) filter (cut-off 100 nm, Sartorius) and 
freeze-dried (Heto-Holten A/S, Allerod, Denmark) for 
48 h at−55°C and at a pressure of 10−2 Torr. The freeze-
dried SLN powder was collected and stored at 4°C. The 
samples obtained by using increasing concentrations 
of protamine were named Pro25, Pro100, and Pro200 
throughout the text.
The re-constitution of the freeze-dried SLN (10 mg) 
was performed in deionized water (2 mL) by means of 
three cycles of vortex (30 s) (Zx3, Velp Scientifica, Milan, 
Italy) followed by a 30 s treatment in an ultrasound bath 
(Sonorex™, Bandelin, Mörfelden, Wan, Germany).
Determination of protamine loading
In order to evaluate the total protamine in the SLN sam-
ples, an accurately weighed amount of freeze-dried SLN 
(~20 mg) was dissolved in 1 mL of dichloromethane. 
Then, 2 mL of deionized water was added and stirred 
until the complete evaporation of the organic sol-
vent. The sediment was separated by centrifugation 
(Spectrafuge 24D, Labnet International Inc., Edison, NJ) 
at 12,000 rpm for 25 min. The protamine total amount 
was determined on the clear supernatant by Bio-Rad 
DC Protein Assay (Bio-Rad laboratories, Milan, Italy), 
measuring the absorbance spectrophotometrically 
(UV/VIS spectrometer V-530, Jasco, Tokyo, Japan) at 
750 nm. The calibration curve for the protamine quan-
tification was linear in the range of 0.1–1 mg/mL with a 
correlation coefficient of R2 = 0.9995. Each sample was 
analyzed in triplicate. The total amount of protamine 
in each sample was expressed as a percentage (% w/w) 
according to the following formula:
Total protamine (%, w/w) = 
determined protamine (mg)
weighed SLN (mg)
 100×
 In order to quantify the protamine fraction non-associ-
ated to the particles (free fraction) an accurately weighed 
amount of freeze-dried SLN (~ 20 mg) was re-constituted 
in deionized water (2 mL) as described above and cen-
trifuged at 10,000 rpm for 15 min in a Microcon device 
(Microcon 10K, Millipore Corporation, Bedford, MA). 
The recovered solution was analyzed for protamine 
concentration (%, w/w) by Bio-Rad DC Protein Assay, as 
referred above. Each sample was analyzed in triplicate. 
The percentage of free protamine was calculated using 
the following formula:
Free protamine (%, w/w) = 
determined free protamine (mg)
weighed SLN (mg)
100×
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 The protamine fraction associated to the nanocarrier 
was calculated from the difference between total and 
free protamine amounts. The data are averaged on three 
determinations for each sample.
Plasmid DNA production
The plasmid vector expressing Enhanced Green Fluorescent 
Protein pEGFP-C3 (pDNA) was transformed into 
Escherichia coli (XL
1
 Blue MR). A Maxiprep from 500 mL 
of the overnight culture was performed by Invitrogen Kit 
according to the manufacturer’s instruction (PureLink™ 
Hipure Plasmid Maxiprep Kit, Invitrogen, Carlbad, CA).
Preparation of SLN:pDNA complexes
pDNA was mixed with freeze-dried SLN (Pro25, Pro100, 
Pro200) re-dispersed in water (5 mg/mL) at the following 
SLN:pDNA w/w ratios: 20:1, 40:1, 60:1, and 80:1. The mix-
tures were kept at room temperature (25 ± 0.5°C) for 45 min 
to allow the formation of the complexes. The water sus-
pensions containing the complexes, named Pro25:pDNA, 
Pro100:pDNA, and Pro200:pDNA throughout the text, 
were used immediately after their preparation.
Physical characterization of SLN and SLN:pDNA 
complexes
Z-average diameter, size distribution, and polydisper-
sity index (PDI) measurements were performed using 
dynamic light scattering (DLS) by a Nanosizer NanoZS 
(Malvern Instruments, Worcs, UK) equipped with a 4 
mW He-Ne laser (633 nm) and a DTS software (Version 
5.0). The value of Z-average diameter is referred to as 
the mean hydrodynamic diameter weighted according 
to light scattering intensity. The size distribution, i.e., 
the plot of the relative intensity of light scattered by par-
ticles in various size classes, was reported as the peak of 
the most represented dimensional class of each particle 
population.
The zeta potential values were determined by Laser 
Doppler Anemometry by a folded capillary electropho-
resis cell of the Zetasizer NanoZS at 25°C using deionized 
water with a refraction index of 1.33 and a viscosity of 
0.8872 cP.
All the data were expressed as the mean ± standard 
deviation (SD) calculated on three determinations.
Atomic force microscopy
The morphology of SLN and the structure of SLN:pDNA 
complexes were examined by Atomic Force Microscopy 
(AFM) (Park Autoprobe Atomic Force Microscope, Park 
Instruments, Sunnyvale, CA). The experiments were car-
ried out in water at room temperature (20 ± 1°C) under 
atmospheric pressure operating in non-contact mode. 
Triangular silicon tips were used for this analysis. The reso-
nant frequency of this cantilever was found to be ~120 KHz.
Agarose gel electrophoresis
The SLN:pDNA complexes were prepared by using 1 µL of 
a pDNA solution at a concentration of 0.5 mg/mL diluted 
in serum-free DMEM medium (1:5, v/v), following the 
same procedure outlined above. The analysis by agarose 
gel electrophoresis was performed at 50 V for 4 h in 0.8% 
(w/v) agarose gel in TBE buffer (0.045 M Tris-borate 
pH 8.3 and 0.001 M EDTA) after adding to each sample 
the loading buffer (40% v/v glycerol and 0.25% w/v 
bromophenol blue in TBE buffer). The results of pDNA 
migration were visualized under UV light, after staining 
with ethidium bromide. The total amount of pDNA in 
each lane was 0.5 µg for all the samples.
Cell culture
COS-I (SV-40 transformed African Green Monkey kidney 
cell line) and HepG2 (Human hepatocellular liver car-
cinoma cell line) cells were cultured in DMEM medium 
with high glucose, supplemented with 10% (v/v) of fetal 
bovine serum (FBS), 100 units/mL penicillin, and 100 
µg/mL streptomycin in a 5% CO
2
 incubator at 37°C under 
95% relative humidity. Na1300 cells (murine neuroblas-
toma cell line) were cultured in the same conditions, but 
using FBS at 20% (v/v).
Cytotoxicity
SLN cytotoxicity, expressed as a percentage of dead cells, 
was assessed by the PI (propidium iodide) test using flow 
cytometry. The cells were seeded at 500,000 cells/dish in 
6 cm Petri dishes and then cultured for 24 h in complete 
medium at 37°C. The experiments were conducted at 
~80% confluence. The medium was aspirated from each 
dish and replaced with 2 mL of serum-free DMEM. Then, 
40, 80, 120, or 160 µL/well of SLN suspension at a con-
centration of 5 mg/mL (corresponding to SLN amounts 
of 0.2, 0.4, 0.6, and 0.8 mg/well, respectively) were added 
followed by 12 h cell incubation. The cytotoxicity of 
polyethilenimmine (PEI), used as a positive control, was 
determined by incubating the cells with 15 µg of PEI for 
2 h in complete medium according to the literature pro-
cedure (Pintel & Tullis, 2006).
Then, all the treated cells were washed with PBS, added 
with 5 mL of DMEM containing FBS (10% v/v), and incu-
bated at 37°C for 24 h, in order to simulate the transfec-
tion procedure, before the flow cytometry analysis.
Cell transfection
In order to study the transfection efficiency of the vectors, 
cells were grown in 6 cm Petri dishes, seeding the cells 
at 500,000 cells/dish. After plating, the cells were incu-
bated at 37°C for 24 h and transfection experiments were 
conducted at ~ 80% confluence. The culture medium was 
aspirated from each dish, replaced with 2 mL of serum-
free medium, and added with SLN:pDNA complexes at 
w/w ratios ranging from 20:1–60:1. The complexes were 
prepared as described above by using 10 µL of 1 mg/mL 
pDNA solution and appropriate volumes of 5 mg/mL 
SLN suspensions. The cells were incubated in a 5% CO
2
 
incubator at 37°C for 12 h (incubation time). Then, the 
transfected cells were washed with PBS and incubated at 
37°C in 5 mL DMEM containing FBS for 24 h (expression 
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time) in order to allow the expression of the protein, and 
then analysed by flow cytometry.
Cells transfected by 10 µg of naked pDNA were used 
as a negative control and cells transfected by PEI:pDNA 
poliplexes were adopted as a positive control. In the 
last case the procedure described in the literature has 
been followed (Pintel & Tullis, 2006; Huh et al., 2007); 
in practice, 2 µg of plasmid DNA was incubated with 
15 µg of PEI for 8 min at room temperature in order to 
obtain stable polyplexes with a w/w ratio of 7.5:1. The 
PEI:pDNA polyplexes were incubated with the cells 
for 2 h (first incubation time) in complete medium 
(DMEM+10% v/v FBS). Then, the medium was replaced 
with 5 mL of fresh complete medium and the cells were 
incubated for 12 h (second incubation time) at 37°C. 
Before the flow cytometry analysis, another medium 
replacement was carried out and the cells were incu-
bated again for 24 h (expression time), likewise for 
SLN:pDNA complexes.
Flow cytometry analysis
Cytotoxicity expressed as a percentage of dead cells as 
well as quantitative transfection efficiency was evaluated 
by flow cytometry. The incubated cells were washed with 
500 µL of PBS and detached with 500 µL of 0.25% trypsin 
added with EDTA (1% v/v).
With regard to cytotoxicity, 800 µl of cells re-suspended 
in 4 mL of the removed medium were centrifuged at 
1000 rpm for 5 min. The supernatant was removed and 
the cells were suspended in 500 µL of PI solution, pre-
pared according to Nicoletti staining (50 mg/mL PI, 0.1% 
w/v sodium citrate, 0.1% w/v Triton X-100), and incu-
bated in the dark at 4°C for 10 min.
For the transfection experiments, 500 µL of detached 
cells re-suspended in 5 mL of DMEM with serum were 
analyzed in order to assay the expression of EGFP.
The percentage of dead cells and the transfection 
efficiency were determined at 540 nm and 488 nm, 
respectively, by using a Coulter Epics XL cytofluorimeter 
(Coulter Electronics Inc., Hialeah, FL) equipped with a 
488 nm argon laser. At least 10,000 events were collected 
for each sample.
results and discussion
Protamine loading
In all SLN samples both the total and the free protamine 
content increased with the increase of the initial amount 
of protamine (Table 1). On the contrary, the protamine 
fraction associated to the nanocarriers, calculated as 
the difference between the total and the free content, 
increased significantly from 4.5% to 13% w/w by increas-
ing the initial amount of protamine in Pro25 and Pro100, 
respectively, and then it remained constant by further 
protamine increase (Pro200), reaching a plateau value. 
The lack of correlation between the increase of initial 
protamine amount and that of the associated protamine 
loading could be explained by considering that protamine 
is localized on the surface of the particles by an ionic 
interaction between its negatively charged amino acid 
tails and the positive amino group of stearylamine (Vighi 
et al., 2010a). Therefore, a saturation of these interac-
tion sites in the Pro100 sample could be reasonably 
supposed.
SLN physical properties
SLN physical properties such as morphology, size, poly-
dispersity index (PDI), and surface charge, known to play 
a critical role in cell transfection efficiency (Rejman et al., 
2004), were investigated.
SLN morphology analysis examined by AFM revealed 
spherical shaped particles in the nanometric size for 
Table 1. Protamine content in SLN samples. Mean values ± SD.
SLN samples
Initial protamine amount in 
the SLN preparation (mg)
Total protamine 
(%, w/w)
Free protamine 
(%, w/w)
Associated protamine 
(%, w/w)
Pro25   25 4.5 ± 0.5 0.00 ± 0.01 4.5 ± 0.5
Pro100 100 23.0 ± 1.5 10.0 ± 0.7 13.0 ± 0.5
Pro200 200 33.4 ± 1.0 20.1 ± 1.0 13.3 ± 0.5
Figure 1. Atomic force microscopy (AFM) images of SLN (A: Pro25; B: Pro100; C: Pro200).
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Pro25 and Pro100, and small particles combined with 
several aggregates for Pro200 (Figure 1). Z-average 
diameters, size distributions by intensity, and zeta 
potential values of the three SLN samples are reported 
in Table 2. According to AFM images, Pro25 and Pro100 
showed no significant differences in Z-average diam-
eters (~230 nm), PDI values of ~0.25, and monomodal 
distributions of the size. Conversely, Pro200 exhibited a 
Z-average diameter of 430 nm, with a higher PDI value 
(~0.5) and a bimodal size distribution characterized 
by two distinct populations being the first one, with 
the main dimensional class at 228 nm (73% intensity), 
attributable to the nanoparticles, and the second one, 
with the main dimensional class at 2446 nm (27% inten-
sity), attributable to particle aggregates. This finding 
confirmed the AFM analysis and suggested that the 
highest initial amount of protamine in the preparation 
(2% w/v) induced particle aggregation, decreasing the 
size homogeneity.
By comparing AFM image with DLS results, it is evi-
dent that plurimodal systems, unlike monomodal ones, 
are not correctly described by the Z-average value. 
Therefore, in such cases the analysis of the size distribu-
tion instead of Z-average has to be considered.
As far as zeta potential is concerned (Table 2), all 
SLN samples showed a positively charged surface 
owing to the presence of the cationic lipid, being the 
value +19 mV, +17 mV, and +9 mV for Pro25, Pro100, 
and Pro200, respectively. The decreased surface 
charge of Pro200 could be attributed to the higher 
free protamine amount accumulated on the nanopar-
ticle surface, inducing a less positive charge than that 
offered by the cationic lipid (Asasutjarit et al., 2007; 
Jain et al., 2009). The reduced zeta potential would 
give an explanation of the nanoparticle aggregation 
observed for this sample.
Agarose gel electrophoresis
To evaluate the ability of the SLN to bind pDNA, an essen-
tial pre-requisite for transfection, gel mobility experiments 
were carried out on the SLN:pDNA complexes obtained at 
different SLN:pDNA ratios (Figure 2). Spots attributable to 
the plasmid migration were provided only by the sample 
Pro25 at SLN:pDNA ratios from 20:1–60:1, indicating that 
pDNA was not stably complexed with the SLN. Otherwise, 
no pDNA migration was observed for the sample Pro25 
at a SLN:pDNA ratio of 80:1 (Figure 2A), as well as for the 
samples Pro100 and Pro200, regardless of the SLN:pDNA 
ratio (Figures 2B and C), giving evidence of a complete 
pDNA complexation. Therefore, the minimum amount of 
protamine able to provide a complete plasmid complex-
ation was found to be ranging from 2.7–3.6 µg/µg pDNA, 
corresponding to the amount of protamine in Pro25 at 80:1 
and in Pro100 at 20:1 SLN:pDNA ratio, respectively.
SLN:pDNA complex physical properties
The results of DLS analysis performed on the SLN:pDNA 
complexes in terms of Z-average diameter, PDI, size dis-
tribution, and zeta potential value are reported in Table 3 
along with the size and the zeta potential of naked pDNA.
With regard to Pro25:pDNA complexes, until 60:1 
SLN:pDNA w/w ratio, a bimodal size distribution was 
observed with PDI values > 0.4. Therefore, the size of each 
population (size distribution by intensity) instead of the 
Z-average value was taken into account, as highlighted 
above. The first population, with the main dimensional 
class at ~210 nm, could be attributable to SLN, whereas 
the second one, at ~580 nm, could be due to the naked 
pDNA. Otherwise, at a 80:1 SLN:pDNA ratio a monomodal 
size distribution with a Z-average diameter of 400 nm 
combined with a low PDI value (0.3) was observed, sug-
gesting the formation of Pro25:pDNA complexes. The 
negative surface charge of pDNA (−27 mV) determined 
an overall negative surface charge for Pro25:pDNA at low 
ratios, owing to the lack of interaction between the plas-
mid and the cationic nanoparticles, with a tendency to 
shift towards positive values as the increase in SLN:pDNA 
ratio, as evidence of the occurred pDNA complexation.
Pro100:pDNA complexes exhibited a monomodal 
size distribution with a Z-average diameter ranging 
between 310–400 nm and PDI values of ~0.4, regard-
less of the SLN:pDNA ratio, suggesting the formation 
of SLN:pDNA complexes. The surface charge was still 
positive and without significant differences according 
to SLN:pDNA ratio, confirming the stable complexation 
of pDNA.
As far as Pro200:pDNA complexes are concerned, a 
high PDI value (>0.5) and three different particle popula-
tions were observed for all SLN:pDNA ratios. The largest 
particles of ~2200 nm could be ascribed to the SLN aggre-
gates, whereas the peak at 350 nm may be attributable to 
the complexes with the plasmid. Moreover, the smallest 
population (90 nm) having a high frequency by intensity 
(~60%) can be presumably provided by protamine/pDNA 
polyplexes according to the high free protamine amount 
found in this sample. This hypothesis is confirmed by the 
positive zeta potential values observed, regardless of the 
SLN:pDNA ratio.
To give further support to the observed SLN:pDNA 
complex physical properties, AFM topographical images 
Table 2. Z-average, PDI, particle size distribution by intensity, and Zeta-potential of Pro25, Pro100, and Pro200. Mean values ± SD.
SLN samples Z-average (nm) (PDI )
Particle size distribution by intensity
Zeta potential (mV)Peak 1 (nm) (%) Peak 2 (nm) (%)
Pro25 230 ± 30 (0.220 ± 0.002) 202 ± 25 (100 ± 2%) — +17 ± 5
Pro100 235 ± 20 (0.280 ± 0.001) 204 ± 22 (100 ± 3%) — +19 ± 3
Pro200 428 ± 80 (0.502 ± 0.004) 228 ± 18 (73 ± 2%) 2446 ± 158 (27 ± 3%) +9 ± 2
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were acquired for SLN:pDNA complexes at a 60:1 ratio 
(Figure 3). Pro25:pDNA image revealed the presence of 
a pDNA coil, indicating the incomplete pDNA complex-
ation in accordance with electrophoresis and DLS data. 
Pro100:pDNA exhibited homogeneous and globular 
structures, suggesting a wrapping of the pDNA around 
the particles. On the contrary, Pro200:pDNA appeared 
as a non-homogenous system with globular particles 
combined with small and irregular shaped structures, 
whereas no free pDNA was observed in agreement to 
DLS and gel electrophoresis results.
Therefore, Pro25 at 80:1 SLN:pDNA ratio, Pro100 
and Pro200 at all the SLN:pDNA ratios were able to 
condense pDNA forming complexes 300–400 nm in 
size. Furthermore, Pro200 sample, having a higher free 
protamine content, led to the coexistence of smaller 
protamine/pDNA polyplexes along with large aggregates 
of SLN. Because of their pDNA immobilization ability 
as well as positive surface charge allowing the interac-
tion with negatively charged cell membranes, these 
SLN:pDNA complexes were selected to be further stud-
ied for transfection efficiency.
Cytotoxicity
Before the transfection studies, cytotoxicity of SLN was 
evaluated on three different cell lines, i.e., COS-I, HepG2, 
and Na1300, by measuring the percentage of dead cells 
using PI test. The experiments were performed using SLN 
amounts ranging between 0.2–0.8 mg/well for Pro100 
and Pro200 and 0.8 mg/well for Pro25. Cells incubated 
in the presence of PEI were used as the positive control; 
untreated cells and cells incubated with naked pDNA as 
the negative ones.
As far as COS-I cells are concerned, Pro25 (0.8 mg/well) 
demonstrated the highest cytotoxicity, whereas Pro100 and 
Pro200 induced a cell death which essentially increased 
with an increase of the SLN:pDNA ratio, reaching a value 
comparable to that of positive control (PEI) (Figure 4A). By 
considering HepG2 and Na1300, no relevant differences 
were observed between the samples which showed a cyto-
toxicity lower than that of the positive control. Moreover, 
the degree of cytotoxicity on HepG2 and Na1300 cells was 
found negligible and 5-fold lower compared with COS-I 
cell line, respectively (Figures 4B and C).
Therefore, SLN exhibited toxic effect on cell lines 
decreasing in the following order: COS-I > Na1300 > 
Figure 2. (A) Agarose gel electrophoresis of pDNA incubated with Pro25 and diluted in DMEM. Lane from left: naked plasmid DNA (0); 
Pro25:pDNA mixtures at 20:1, 40:1, 60:1, and 80:1 w/w ratios, respectively. (B) Agarose gel electrophoresis of pDNA incubated with Pro100 
and diluted in DMEM. Lane from left: naked plasmid DNA (0); Pro100:pDNA mixtures at 20:1, 40:1, 60:1, and 80:1 w/w ratios, respectively. 
(C) Agarose gel electrophoresis of pDNA incubated with Pro200 and diluted in DMEM. Lane from left: naked plasmid DNA (0); Pro200:pDNA 
mixtures at 20:1, 40:1, 60:1, and 80:1 w/w ratios, respectively.
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HepG2 according to the increasing cell lipid metabo-
lism rate COS-I < Na1300 < HepG2 (Gröne, 1994; Karten 
et al., 2005; Guo et al., 2006). The faster lipid metabolism 
rate is provided by cells the faster the degradation of the 
up-taken particles and, consequently, the stronger the 
cell toxicity prevention will result.
Otherwise, PEI demonstrated the same cytotoxicity on 
all the three tested cell lines because of its strongly positive 
charge and because its degradation pathway was unaf-
fected by the cellular metabolism (Moghimi et al., 2005).
Transfection experiments
Tranfection experiments were carried out by flow cytom-
etry using the same SLN amounts used in the cytotoxicity 
experiments; naked pDNA and PEI were used as negative 
and positive control, respectively. Sample Pro25, having 
the lowest protamine level which was unable to reduce 
the toxicity of the lipid matrix and to protect COS-I cells 
against apoptosis, was excluded from the transfection 
assay on such a cell line.
Compared with the gene transfection efficiency of 
the plasmid, Pro25:pDNA and Pro200:pDNA complexes 
were unable to improve transfection efficiently, regard-
less of the cell line and the SLN:pDNA ratio (Figure 5). On 
the contrary, Pro100:pDNA complexes at the SLN:pDNA 
ratio providing the best transfection efficiency (40:1) 
improved the transfection capacity of the naked pDNA 
5-fold on COS-I cells, 7-fold on HepG2 cells, and 12-fold 
on Na1300 cells. By considering the level of the transfec-
tion mediated by PEI, the efficiency of Pro100:pDNA at 
the same SLN:pDNA ratio was lower on both COS-I and 
HepG2 cell line (4-fold and 7-fold, respectively), but 
2-fold higher on Na1300 cells.
Therefore, protamine amount plays an important role 
in determining the transfection performance of SLN. The 
insufficient protamine content could reasonably justify 
the failure in cell transfection of Pro25:pDNA complexes; 
on the other hand, the presence of an excess of protamine 
inducing the formation of protamine:pDNA polyplexes, 
incapable to transfect the cells efficiently owing to either 
their inability to overcome the cell membrane (Liu 
et al., 2009) or their strong pDNA binding (Mayer et al., 
2005), could explain the poor transfection capacity of 
Table 3. Z-average, PDI, particle size distribution by intensity, and Zeta-potential SLN:pDNA complexes at w/w ratios from 20:1 to 80:1, 
in comparison with naked pDNA. Mean values ± SD.
 SLN:pDNA (w/w) Z-average (nm) (PDI)
Particle size distribution by intensity
Zeta 
potential
Peak 1 (nm) (%) Peak 2 (nm) (%) Peak 3 (nm) (%) (mV)
Naked pDNA — 530 ± 15 (0.477 ± 0.05) 580 ± 40 (100 ± 2%) — — −27 ± 3
Pro25:pDNA 20:1 320 ± 25 (0.483 ± 0.03) 210 ± 15 (40 ± 4%) 570 ± 32 (60 ± 6%) — −12 ± 2
40:1 330 ± 30 (0.545 ± 0.04) 212 ± 21 (50 ± 3%) 581 ± 36 (50 ± 4%) — −8 ± 3
60:1 410 ± 24 (0.504 ± 0.06) 208 ± 19 (65 ± 4%) 575 ± 39 (35 ± 5%) — +7 ± 1
80:1 406 ± 19 (0.302 ± 0.08) 350 ± 45 (100 ± 2%) — — +16 ± 2
Pro100:pDNA 20:1 330 ± 15 (0.352 ± 0.02) 325 ± 15 (100 ± 2%) — — +21 ± 3
40:1 310 ± 33 (0.427 ± 0.01) 333 ± 23 (100 ± 3%) — — +18 ± 2
60:1 405 ± 28 (0.323 ± 0.03) 350 ± 33 (100 ± 3%) — — +17 ± 4
80:1 400 ± 42 (0.401 ± 0.05) 348 ± 35 (100 ± 2%) — — +18 ± 3
Pro200:pDNA 20:1 268 ± 33 (0.544 ± 0.02) 90 ± 11 (20 ± 3%) 330 ± 22 (50 ± 3%) 2022 ± 152 (30 ± 3%) +14 ± 3
40:1 261 ± 51 (0.619 ± 0.05) 85 ± 15 (33 ± 2%) 351 ± 18 (57 ± 5%) 2050 ± 159 (10 ± 4%) +15 ± 4
60:1 267 ± 43 (0.702 ± 0.08) 88 ± 14 (35 ± 4%) 325 ± 23 (62 ± 2%) 2111 ± 148 (30 ± 3%) +16 ± 5
80:1 275 ± 48 (0.502 ± 0.07) 93 ± 8 (32 ± 3%) 340 ± 25 (65 ± 4%) 2502 ± 169 (30 ± 2%) +13 ± 3
Figure 3. Atomic force microscopy (AFM) images at 60:1 
SLN:pDNA ratio of Pro25:pDNA (A), Pro100:pDNA (B), and 
Pro200:pDNA (C) complexes.
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Pro200:pDNA. Contrary to this, Pro100:pDNA seems to 
contain the optimal protamine amount able to promote 
the transfection capacity of the carrier. Moreover, since 
protamine is an arginine rich peptide like TAT of HIV, and 
since HIV is able to provide a brain reservoir owing to the 
presence of TAT (Zink et al., 1999; Van der Meer et al., 
2000), protamine may play a role in the active internal-
ization process by neuronal Na1300 cells.
conclusions
The amount of protamine, used as a pDNA condenser and 
cell transfer enhancer in the development of lipid nano-
particles, strongly affects the plasmid condensation and 
the gene transfection efficiency. Only protamine amount 
used in Pro100 preparation allowed us to obtain nanopar-
ticles able to stabilize SLN:pDNA complexes promoting 
the plasmid wrapping around the particles and achieving 
Figure 4. Cytotoxicity expressed as a percentage of dead cells of Pro25, Pro100, and Pro200 on COS-I (A), HepG2 (B), and Na1300 (C) cell 
lines, as provided by PI assay from flow cytometry analysis.
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a successful tropism for a neuronal cell line, known to be 
poorly transfectable. Since the objective of gene therapy 
is to obtain targeted vectors transferring genes efficiently 
to specific cell types, the proposed nanocarrier could be 
considered in a perspective of DNA-based pharmaceuti-
cals for the management of brain-associated disorders.
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D
ow
nl
oa
de
d 
by
 [U
niv
 M
od
en
a e
 R
eg
gio
 E
mi
lia
 B
U]
, [
El
ian
a L
eo
] a
t 0
8:1
0 0
9 S
ep
tem
be
r 2
01
5 
10 E. Vighi et al.
 Drug Delivery
Declaration of interest
The authors report no conflicts of interest.
references
Asasutjarit, R., Lorenzen, S.I., Sirivichayakul, S., Ruxrungtham, K., 
Ruktanonchai, U., Ritthidej, G.C. (2007). Effect of solid lipid 
nanoparticles formulation composition on their size, zeta potential 
and potential for in vitro pHIS-HIV-Hugag transfection. Pharm 
Res. 24:1098–7.
Braun, R.E. (2001). Packaging paternal chromosomes with protamina. 
Nat Genet. 28:10–12.
Canine, B.F., Wang, Y., Hatefi, A. (2008). Evaluation of the effect of 
vector architecture on DNA condensation and gene transfer 
efficiency. J Contr Rel. 129:117–23. 
Del Pozo-Rodríguez, A., Delgado, D., Solinís, M.A., Gascon, A.R., 
Pedraz, J.L. (2007). Solid lipid nanoparticles: Formulation factors 
affecting cell transfection capacity. Int J Pharm. 339: 261–8.
Del Pozo-Rodríguez, A., Solinís, M.A., Gascón, A.R., Pedraz, J.L.(2009). 
Short- and long-term stability study of lyophilized solid lipid 
nanoparticles for gene therapy. Eur J Pharm Biopharm. 71:181–9.
Gröne, E.F., Walli, A.K., Gröne, H.J., Miller, B., Seidel, D. (1994). 
The role of lipids in nephrosclerosis and glomerulosclerosis. 
Atherosclerosis. 107:1–13.
Guo, W., Huang, N., Cai, J., Xie, W., Hamilton, J.A. (2006). Fatty acid 
transport and metabolism in HepG2 cells. J Physiol Gastrointest 
Liver Physiol. 290:528–34.
Heydenrich, A.V., Westmeier, R., Pedersen, N., Polsen, H.S., Kristensen, 
H.G. (2003). Preparation and purification of cationic solid lipid 
nanospheres-effect on particle size, physical stability and cell 
toxicit. Int J Pharm. 254:355–64.
Huang, L., Viroonchatapan, E. (1999). Introduction. In: Huang, L., 
Wagner, M., ed. Nonviral vectors for gene therapy. New York: 
Academic Press, 39–68. 
Huh, S.H., Do, H.J., Lim, H.Y., Kim, D.K., Choi, S.J., Song, H., Kim, 
N.H., Park, J.K., Chang, W.K., Chung, H.M., Kim, J.H. (2007). 
Optimazation of 25 KDa linear polyethylenimine for efficient gene 
delivery. Biologicals. 35:165–71.
Jain, V., Prasad, V., Jadhav, P., Mishra, P.R. (2009). Preparation and 
performance evaluation of saquinavir laden cationic submicron 
emulsions. Drug Deliv. 16:37–44.
Karten, B., Hayashi, H., Campenot, R.B., Vance, D.E., Vance, J.E. 
(2005). Neuronal models for studying lipid metabolism and 
transport. Methods. 36:117–28. 
Liu, J., Guo, S., Li, Z., Liu, L., Gu, J. (2009). Synthesis and characterization 
of stearyl protamine and investigation of their complexes with 
DNA for gene delivery. Coll Surf B: Bioint. 73:36–41.
Mayer, G., Vogel, V., Weyermann, J., Lochmann, D., van den Broek, J.A., 
Tziatzios, C., Haase, W., Wouters, D., Schubert, U.S., Zimmer, A., 
Kreuter, J., Schubert, D. (2005). Oligonucleotide–protamine-albumin 
nanoparticles: Protamine sulfate causes drastic size reduction. J 
Contr Rel. 106:181–7.
Moghimi, S.M., Symonds, P., Murray, J.C., Hunter, A.C., Debska, G., 
Szewczyk, A. (2005). A two-stage poly(ethylenimine)-mediated 
cytotoxicity: Implications for gene transfer/therapy. Mol Ther. 
11:990–5.
Morille, M., Passirani, C., Vonarbourg, A., Clavreul, A., Benoit, J.P. 
(2008). Progress in developing cationic vectors for non viral 
systemic gene therapy against cancer. Biomaterials. 29:3477–96.
Olbrich, C., Bakowsky, U., Lehr, C.M., Muller, R.H., Kneuer, C. (2001). 
Cationic solid–lipid nanoparticles can efficiently bind and transfect 
plasmid DNA. J Contr Rel. 77:345–55.
Pedersen, N., Hansen, S., Heydenreich, A.V., Kristensen, H.G., Poulsen, H.S. 
(2006). Solid lipid nanoparticles can effectively bind DNA, streptavidin 
and biotinylated ligands. Eur J Pharm Biopharm. 62:155–62.
Pintel, D.J., Tullis, G.E. (2006). Transfection of mammalian cells 
using linear polyethylenimine is a simple and effective means of 
producing recombinant adeno-associated virus vectors. J Virol 
Methods. 138:85–98.
Rejman, J., Oberie, V., Zuhon, I.S., Hoekstra, D. (2004). Size-dependent 
internalization of particles via pathways of clathrin and cavoelae-
mediated endocytosis. Biochem J. 377:159–69.
Rudolph, C., Schillinger, U., Ortiz, A., Tabatt, K., Plank, C., Müller, R.H., 
Rosenecker, J. (2004). Application of novel solid lipid nanoparticles 
(SLN)-gene vector formulations based on a dimeric HIV-1 Tat-
peptide in vitro and in vivo. Pharm Res. 21:1662–9.
Tabatt, K., Kneuer, C., Sameti, M., Olbrich, C., Muller, R.H., Lehr, 
C.M., Bakowsky, U. (2004a). Transfection with different colloidal 
systems: comparison of solid lipid nanoparticles and liposomes. J 
Contr Rel. 97:321–32.
Tabatt, K., Sameti, M., Olbrich, C., Muller, R.H., Lehr, C.M. (2004b). 
Effect of cationic lipid and matrix lipid composition on solid lipid 
nanoparticle-mediated gene transfer. Eur J Pharm Biopharm. 
57:155–62.
Tsuchiya, Y., Ishti, T., Okahata, Y., Sato, T. (2006). Characterization of 
Protamine as a tranfection accelerator for gene delivery. J Bioact 
Comp Polym. 21:519–37.
Van der Meer, P., Ulrich, A.M., Gonzalez-Scarano, F., Lavi, E. (2000). 
Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. 
Exp Mol Pathol. 69:233–41.
Vangasseri, D.P., Han, S.J., Huang, L. (2005). Lipid-protamine-DNA-
mediated antigen delivery. Curr. Drug Deliv. 2:401–6.
Vighi, E., Montanari, M., Ruozi, B., Tosi, G., Magli, A., Leo, E. (2010b). Nuclear 
localization of cationic solid lipid nanoparticles containing Protamine 
as transfection promoter. Eur J Pharm Biopharm. 76:384–93.
Vighi, E., Ruozi, B., Montanari, M., Battini, R., Leo, E. (2010a). pDNA 
condensation capacity and in vitro gene delivery properties of 
cationic solid lipid nanoparticles. Int J Pharm. 389:254–61.
Zink, W.E., Zheng, J., Persidsky, Y., Poluektova, L., Gendelman, 
H.E. (1999). The neuropathogenenesis of HIV-1 infection. FEMS 
Immunol Med Mic. 26:233–41.
D
ow
nl
oa
de
d 
by
 [U
niv
 M
od
en
a e
 R
eg
gio
 E
mi
lia
 B
U]
, [
El
ian
a L
eo
] a
t 0
8:1
0 0
9 S
ep
tem
be
r 2
01
5 
